Updated:
LTS Lohmann Therapie-Systeme AG
LTS Lohmann Therapie-Systeme AG is a publicly traded CDMO and family-controlled industrial technology firm, founded in 1984 by Dr.
LTS Lohmann Therapie-Systeme AG
LTS Lohmann Therapie-Systeme AG was founded in Andernach, Germany in 1984 by Dr. Dietrich Lohmann, a chemist who specialized in transdermal drug delivery systems. The company went public in 1999 on the Frankfurt Stock Exchange (ISIN: DE000A3CM708), while the founding family and related entities retain a controlling stake. The firm's core innovation lies in its development and manufacturing of transdermal patches and oral thin-film technologies for both pharmaceutical and consumer health clients. Strategy focuses on partnership-based CDMO work: LTS designs and produces drug delivery systems on contract for major pharmaceutical companies including Bayer, Novartis, and Johnson & Johnson. Its technology platform spans five drug-delivery modalities — transdermal patches, oral thin films, micro-needle arrays, intradermal systems, and wearable injectors. Geographically, manufacturing centers in Andernach (Germany) and Atlanta (Georgia) serve European and North American markets, with a commercial office in New York. Confirmed products include nicotine replacement patches, contraceptive patches, and overactive bladder treatments. The firm employs approximately 1,700 people globally across its three sites. In 2023, LTS reported €654 million in revenue and has consistently invested in capacity expansion. The company is publicly listed but remains under substantial insider control; the largest shareholder is Lohmann family entities. The firm has been engaged in litigation with competitor Corium regarding patent infringement on transdermal technology, with a settlement reached in 2020. Structural differentiator: LTS is a rare hybrid — a publicly traded company that functions operationally as a single-family-office tool, given the controlling stake of the founding family. This structure allows the Lohmann family to access public capital markets while maintaining strategic direction over a specialized industrial technology platform. Succession governance: Dr. Dietrich Lohmann chairs the supervisory board, but management is delegated to non-family executives, separating operational leadership from family ownership.
General information
Firm type
other
Year founded
1984
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Andernach
Corporate office
Andernach, Germany
Additional offices
Atlanta, Georgia, United States · New York, New York, United States
Principals
Dr. Dietrich Lohmann
Founder and Chairman of the Supervisory Board
Sector focus
Frequently asked questions
Who controls investment decisions at LTS Lohmann?
Operational investment decisions are made by the management board, headed by CEO Dr. Axel Krämer, while strategic decisions — including major capital expenditures and acquisition — require approval from the supervisory board chaired by founder Dr. Dietrich Lohmann. The Lohmann family, as controlling shareholders, effectively steers longer-term strategic direction (per public filings).
Is LTS a family office or a public company?
LTS is a publicly traded company (Frankfurt Stock Exchange) but is effectively controlled by the founding Lohmann family, making it a hybrid — a public vehicle that functions partly as a family-operated industrial platform. The majority of voting shares remain under family control.
What investment stages does LTS target?
LTS does not invest in external startups or funds. It operates as a CDMO, meaning it invests capital into expanding its own manufacturing infrastructure and technology platforms. The firm is typically approached by pharmaceutical clients at the clinical stage or later, once a drug candidate requires commercial-scale manufacturing.
Does LTS participate in co-investments alongside external partners?
No. LTS does not function as an investment firm; it is a pure industrial company. Its capital deployment is exclusively into internal capacity expansion, R&D, and manufacturing equipment. The firm has no disclosed track record of co-investing as a limited partner or direct investor.
How does LTS source new business?
Business development is relationship-driven, primarily through existing pharmaceutical relationships developed over 40 years in the CDMO space. LTS uses a dedicated business development team to pitch its drug delivery platforms to pharma and biotech firms, and responds to requests for proposals (RFPs) in the contract manufacturing market.
What sectors does LTS explicitly avoid?
LTS focuses narrowly on transdermal and oral thin-film drug delivery systems. It does not engage in injectable biologics, oral solid dosage forms, or large-molecule drug development. The firm avoids speculative drug discovery and remains technology-platform-specific.
How is LTS related to the Lohmann family wealth?
The Lohmann family's wealth is largely concentrated in LTS through a controlling shareholding. Dr. Dietrich Lohmann, as founder and chairman, represents the family's governance; the family has not disclosed a separate family office entity. The public company structure provides liquidity while the family maintains operational control.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: